| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Kiniksa Pharmaceuticals International, Plc (KNSA) has 13 insiders with recent SEC Form 4 filings, including 7 buys and 2 sells. KNSA is classified in the Pharmaceuticals industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 626.2K | $35.75M | - | |
| Other | 143.9K | $8.21M | - | |
| Dir | 36.5K | $2.08M | - | |
| COO | 28.7K | $1.64M | - | |
| CFO | 22.8K | $1.30M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Feb 14, 2020 | Paolini John F.51 | SVP &Chief Medical Officer | Sale+OE | 11,316 | $18.29 | $207,011.20 | -23.9% | |
| May 29, 2018 | Flynn James E62 | 10% Owner, *possible Member Of 10% Group | Buy | 843,352 | $18.97 | $15,996,834.49 | +55.3% | |
| May 29, 2018 | Cormorant Asset Management, LP49 | 10% Owner | Buy | 69,444 | $18.00 | $1,249,992.00 | +8.4% | |
| May 29, 2018 | Baker Bros. Advisors LP59 | Director, 10% Owner | Buy | 3,000,000 | $18.00 | $54,000,000.00 | New |